On 15 October 2014, orphan designation (EU/3/14/1339) was granted by the European Commission to GW Pharma Ltd, United Kingdom, for cannabidiol for the treatment of Dravet syndrome.
The sponsorship was transferred to GW Research Ltd, United Kingdom, in November 2017.
The sponsorship was transferred to GW Pharma (International) B.V., the Netherlands, in April 2019.
Cannabidiol treatment of Dravet syndrome and treatment of Lennox-Gastaut has been authorised in the EU as Epidyolex since 19 September 2019.
|Disease / condition||
Treatment of Dravet syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.